• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌感染的流行病学

Epidemiology of Clostridium difficile infection.

作者信息

Depestel Daryl D, Aronoff David M

机构信息

Medical Affairs, Cubist Pharmaceuticals Inc, Lexington, MA, USA.

出版信息

J Pharm Pract. 2013 Oct;26(5):464-75. doi: 10.1177/0897190013499521.

DOI:10.1177/0897190013499521
PMID:24064435
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4128635/
Abstract

There has been dramatic change in the epidemiology of Clostridium difficile infection (CDI) since the turn of the 21st century noted by a marked increase in incidence and severity, occurring at a disproportionately higher frequency in older patients. Historically considered a nosocomial infection associated with antibiotic exposure, CDI has now also emerged in the community in populations previously considered low risk. Emerging risk factors and disease recurrence represent continued challenges in the management of CDI. The increased incidence and severity associated with CDI has coincided with the emergence and rapid spread of a previously rare strain, ribotype 027. Recent data from the United States and Europe suggest that the incidence of CDI may have reached a crescendo in the recent years and is perhaps beginning to plateau. The acute care direct costs of CDI were estimated to be US$4.8 billion in 2008. However, nearly all the published studies have focused on CDI diagnosed and treated in the acute care hospital setting and fail to measure the burden outside the hospital, including recently discharged patients, outpatients, and those in long-term care facilities. Enhanced surveillance methods are needed to monitor the incidence, to identify populations at risk, and to characterize the molecular epidemiology of strains causing CDI.

摘要

自21世纪之交以来,艰难梭菌感染(CDI)的流行病学发生了显著变化,其发病率和严重程度显著增加,在老年患者中出现的频率尤其高。CDI在历史上被认为是一种与抗生素暴露相关的医院感染,现在也出现在以前被认为低风险的社区人群中。新出现的风险因素和疾病复发仍是CDI管理中的持续挑战。与CDI相关的发病率和严重程度增加与一种以前罕见的菌株——核糖体分型027的出现和迅速传播同时发生。来自美国和欧洲的最新数据表明,近年来CDI的发病率可能已达到顶峰,或许开始趋于平稳。2008年,CDI的急性护理直接成本估计为48亿美元。然而,几乎所有已发表的研究都集中在急性护理医院环境中诊断和治疗的CDI,未能衡量医院外的负担,包括近期出院的患者、门诊患者以及长期护理机构中的患者。需要加强监测方法来监测发病率、识别高危人群,并描述引起CDI的菌株的分子流行病学特征。

相似文献

1
Epidemiology of Clostridium difficile infection.艰难梭菌感染的流行病学
J Pharm Pract. 2013 Oct;26(5):464-75. doi: 10.1177/0897190013499521.
2
Burden of Clostridium difficile on the healthcare system.艰难梭菌对医疗体系的负担。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S88-92. doi: 10.1093/cid/cis335.
3
Current status of Clostridium difficile infection epidemiology.艰难梭菌感染流行病学的现状。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S65-70. doi: 10.1093/cid/cis319.
4
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.艰难梭菌感染(CDI)负担 - 原发性和复发性 CDI 流行病学的系统评价。
BMC Infect Dis. 2021 May 19;21(1):456. doi: 10.1186/s12879-021-06147-y.
5
An Observational Cohort Study of Ribotype 027 and Recurrent Infection.027 型与再感染的观察性队列研究。
mSphere. 2018 May 23;3(3). doi: 10.1128/mSphere.00033-18. eCollection 2018 May-Jun.
6
Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology.新西兰奥克兰地区艰难梭菌作为儿童医疗保健相关腹泻病因的临床及分子流行病学研究
Eur J Clin Microbiol Infect Dis. 2014 Oct;33(10):1741-7. doi: 10.1007/s10096-014-2139-2. Epub 2014 May 9.
7
Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection.目前艰难梭菌感染的流行病学和结局趋势。
Clin Infect Dis. 2015 May 15;60 Suppl 2:S66-71. doi: 10.1093/cid/civ140.
8
Epidemiology of infections, France, 2010 to 2017.2010 年至 2017 年法国传染病的流行病学。
Euro Surveill. 2019 Aug;24(35). doi: 10.2807/1560-7917.ES.2019.24.35.1800638.
9
Outcomes in community-acquired Clostridium difficile infection.社区获得性艰难梭菌感染的结局。
Aliment Pharmacol Ther. 2012 Mar;35(5):613-8. doi: 10.1111/j.1365-2036.2011.04984.x. Epub 2012 Jan 10.
10
Consequences of Clostridium difficile infection: understanding the healthcare burden.艰难梭菌感染的后果:了解医疗负担。
Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12. doi: 10.1111/1469-0691.12064.

引用本文的文献

1
Risk factors for further recurrences of Clostridioides difficile infection at the first and second recurrence: a retrospective cohort.艰难梭菌感染首次和第二次复发时进一步复发的危险因素:一项回顾性队列研究。
BMC Infect Dis. 2025 Aug 22;25(1):1057. doi: 10.1186/s12879-025-11495-0.
2
Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection.接受粪便微生物群、活-jslm(RBL)治疗以预防艰难梭菌反复感染的患者的特征及真实世界结局
Infect Dis Ther. 2025 Apr;14(4):793-802. doi: 10.1007/s40121-025-01130-5. Epub 2025 Mar 21.
3
A mixed-methods study assessing the performance of a clinical decision support tool for testing for patients receiving laxatives.一项混合方法研究,评估一种用于接受泻药治疗患者检测的临床决策支持工具的性能。
Infect Control Hosp Epidemiol. 2025 Mar 13;46(5):1-7. doi: 10.1017/ice.2025.30.
4
Infections and Antibiotherapy: Results of Four Years of Observation in a Romanian Tertiary Hospital.感染与抗生素治疗:罗马尼亚一家三级医院四年观察结果
Microorganisms. 2024 Dec 3;12(12):2490. doi: 10.3390/microorganisms12122490.
5
A New Convenient Method to Assess Antibiotic Resistance and Antimicrobial Efficacy against Pathogenic Biofilms.一种评估针对致病性生物膜的抗生素耐药性和抗菌效果的便捷新方法。
Antibiotics (Basel). 2024 Aug 3;13(8):728. doi: 10.3390/antibiotics13080728.
6
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection.PUNCH CD3 - OLS:一项3期前瞻性观察队列研究,旨在评估粪便微生物群活菌制剂(REBYOTA)在复发性艰难梭菌感染成人患者中的安全性和有效性。
Clin Infect Dis. 2025 Feb 5;80(1):43-51. doi: 10.1093/cid/ciae437.
7
Healthcare-associated Diarrhea due to in Patients Attending a Tertiary Care Teaching Hospital of North India.印度北部一家三级护理教学医院就诊患者中由[具体病因未给出]引起的医疗保健相关腹泻
Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):60-64. doi: 10.5005/jp-journals-10018-1429.
8
Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non- Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study.粪便微生物群制剂Live-jslm(REBYOTA®)在接受非感染性抗生素治疗患者中的疗效:一项2期开放标签研究的事后亚组分析
Open Forum Infect Dis. 2024 Jun 17;11(7):ofae341. doi: 10.1093/ofid/ofae341. eCollection 2024 Jul.
9
Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy under enforcement discretion for the prevention of recurrent infection.粪便微生物群的回顾性亚组分析,即结肠镜检查根据执法裁量权给予的活-jslm(REBYOTA)用于预防复发性感染。
Therap Adv Gastroenterol. 2024 Mar 24;17:17562848241239547. doi: 10.1177/17562848241239547. eCollection 2024.
10
Infection in Hospitalized Patients-A Retrospective Epidemiological Study.住院患者感染——一项回顾性流行病学研究
Healthcare (Basel). 2023 Dec 29;12(1):76. doi: 10.3390/healthcare12010076.

本文引用的文献

1
Deaths: preliminary data for 2008.死亡情况:2008年初步数据。
Natl Vital Stat Rep. 2010 Dec;59(2):1-52.
2
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.艰难梭菌感染的诊断、治疗和预防指南。
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.
3
Reply to Walker et al.对沃克等人的回复
Clin Infect Dis. 2013 Jun;56(12):1846-7. doi: 10.1093/cid/cit099. Epub 2013 Feb 18.
4
Regarding "Clostridium difficile ribotype does not predict severe infection".关于“艰难梭菌核糖体分型不能预测严重感染”。
Clin Infect Dis. 2013 Jun;56(12):1845-6. doi: 10.1093/cid/cit098. Epub 2013 Feb 18.
5
The epidemiology of Clostridium difficile infection in children: a population-based study.儿童艰难梭菌感染的流行病学:一项基于人群的研究。
Clin Infect Dis. 2013 May;56(10):1401-6. doi: 10.1093/cid/cit075. Epub 2013 Feb 13.
6
Community-associated Clostridium difficile infection: how real is it?社区获得性艰难梭菌感染:它有多真实?
Anaerobe. 2013 Dec;24:121-3. doi: 10.1016/j.anaerobe.2013.01.006. Epub 2013 Feb 8.
7
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
8
All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study.住院艰难梭菌感染患者的全因和疾病特异性死亡率:一项多中心队列研究。
Clin Infect Dis. 2013 Apr;56(8):1108-16. doi: 10.1093/cid/cis1209. Epub 2013 Jan 8.
9
Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection.目前或近期患有艰难梭菌感染的患者中不必要的抗菌药物使用。
Infect Control Hosp Epidemiol. 2013 Feb;34(2):109-16. doi: 10.1086/669089. Epub 2012 Dec 19.
10
Microevolutionary analysis of Clostridium difficile genomes to investigate transmission.艰难梭菌基因组的微观进化分析以研究传播情况。
Genome Biol. 2012 Dec 21;13(12):R118. doi: 10.1186/gb-2012-13-12-r118.